- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 22.05. | Sanofi gains experimental Alzheimer's drug through Vigil buyout | ||
| 22.05. | House passes reconciliation bill with massive Medicaid cuts | ||
| 22.05. | Novo pressures GLP-1 compounders as FDA ban takes hold | ||
| 22.05. | FDA advisers pan Pfizer's PARP drug; Sarepta to resume Duchenne study | ||
| 21.05. | Reproductive health startup raises $65M for infertility drugs | ||
| 21.05. | FDA panel backs Darzalex for early stage multiple myeloma | ||
| 21.05. | Moderna pulls application for combo COVID, flu shot | ||
| 21.05. | Roche strikes Orionis deal to develop 'molecular glues' for cancer | ||
| 20.05. | FDA sets stricter approval standards for COVID vaccines | ||
| 20.05. | Tourmaline Bio shares fall on Phase 2 data; Schrödinger cuts staff | ||
| 20.05. | Pfizer buys into PD-1/VEGF competition with 3SBio deal | ||
| 19.05. | Prime Medicine claims 'proof of concept,' but lays off staff in pivot | ||
| 19.05. | Novavax's COVID vaccine gets FDA approval, but with limits | ||
| 19.05. | Regeneron wins bid to buy 23andMe out of bankruptcy | ||
| 19.05. | FDA OKs first blood test to aid Alzheimer's diagnosis | ||
| 19.05. | How regulatory convergence is raising the bar for sterile drug safety-and how West leads the way | ||
| 19.05. | From insight to impact: How eCOAs strengthen trial data quality | ||
| 19.05. | Bridging the data gaps that impact retail and specialty-lite success | ||
| 16.05. | BioMarin to buy rare disease drugmaker Inozyme for $270M | ||
| 16.05. | Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff | ||
| 16.05. | Novo CEO to depart as obesity drugmaker's challenges rise | ||
| 15.05. | A bespoke CRISPR therapy suggests a blueprint for treating 'N-of-1' diseases | ||
| 15.05. | FDA delays approval decision for Biohaven rare disease drug | ||
| 15.05. | Sanofi to pour more than $20B into US drug research and manufacturing | ||
| 15.05. | AbbVie stakes $335M on a startup's RNAi drugs |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .